On November 5, 2018 NantKwest (NASDAQ: NK), a leading, clinical-stage natural killer cell-based therapeutics company, reported that the company will be making multiple presentations associated with the company’s off-the-shelf CD16 targeted NK cell (hanK) and NANT Cancer Vaccine platform at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Conference which runs from November 7 – 11 in Washington D.C (Press release, NantKwest, NOV 5, 2018, View Source [SID1234530743]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SITC Conference Details:
Title:
First in human data in advanced solid tumors of NANT Cancer Vaccine: A novel temporospatial orchestration of the innate (NK) & adaptive immune system to induce antigen cascade & immunogenic cell death
Session: Immune Escape: Currently Understanding of Mechanisms and Advances in Therapeutics Approaches
Date/Time: Wednesday, November 7, 2018, 5:45pm EST
Type: Oral Presentation
Title:
NANT Cancer Vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activate NK and T cell therapy in patients with third-line or greater metastatic pancreatic cancer
Date: Friday, November 9, 2018
Type: Poster Presentation/Abstract #P713
Location: Hall E
Title:
NANT Cancer Vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activate NK and T cell therapy in patients with third-line or greater TNBC and head & neck cancer
Date: Saturday, November 10, 2018
Type: Poster Presentation/Abstract #P310
Location: Hall E